Abstract
Tedizolid is a novel antibiotic of the class of oxazolidinones. This review evaluates the published literature on the optic and peripheral neuropathy associated with short and prolonged administration of tedizolid.
A review of published data from 4 databases was conducted, regarding the development of optic and peripheral neuropathy in patients who received tedizolid for short or prolonged duration. A total of 1,212 records were screened; 33 were included in this review. No peripheral or optic neuropathy cases were reported in 6 randomized controlled trials that studied tedizolid use for a short course. In contrast, 2 cases with optic neuropathy (1 not supported by objective findings) in 87 patients of the prospective studies were identified. Additionally, in a total of 277 patients who participated in the 6 retrospective studies, 9 adverse events related to optic or peripheral neuropathy and 1 case with foot drop in 22 patients of the relevant cases reports were recorded.
The available data suggests that the safety profile of tedizolid is favorable, especially when given for a short time. However, more clinical studies are needed regarding its long-term use, given that the neurotoxicity induced by oxazolidinones may be time and dose-dependent.